Matisse Pharmaceuticals closed a Series A financing round to advance isupartob sodium through phase 2 clinical development.
Matisse Pharmaceuticals is a biopharmaceutical clinical stage company developing innovative therapies targeting life-threatening inflammation, specifically focusing on sepsis and septic shock by neutralizing extracellular cytotoxic histones
Matisse Pharmaceuticals is a biopharmaceutical clinical stage company developing innovative therapies targeting life-threatening inflammation, specifically focusing on sepsis and septic shock by neutralizing extracellular cytotoxic histones.